Replimune Group, Inc. $REPL Shares Bought by TD Asset Management Inc

Key Points

• TD Asset Management Inc increased its stake in Replimune Group by 18.7% during Q2, owning 327,452 shares worth approximately $3.04 million.
• The stock's performance shows a 52-week range between $2.68 and $17.00, with a current market cap of $697.86 million.
• Analysts have mixed ratings for Replimune Group, with five recommending a Buy and some cutting their price targets significantly, indicating volatility and uncertainty in future performance.

TD Asset Management Inc raised its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 18.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 327,452 shares of the company's stock after acquiring an additional 51,600 shares during the period. TD Asset Management Inc owned approximately 0.42% of Replimune Group worth $3,042,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of REPL. Moody Aldrich Partners LLC acquired a new stake in Replimune Group in the 1st quarter valued at about $1,925,000. Bank of New York Mellon Corp raised its holdings in Replimune Group by 8.4% in the 1st quarter. Bank of New York Mellon Corp now owns 189,177 shares of the company's stock valued at $1,844,000 after acquiring an additional 14,659 shares during the last quarter. Arizona State Retirement System raised its holdings in Replimune Group by 19.7% in the 1st quarter. Arizona State Retirement System now owns 15,439 shares of the company's stock valued at $151,000 after acquiring an additional 2,545 shares during the last quarter. Victory Capital Management Inc. raised its holdings in Replimune Group by 67.4% in the 1st quarter. Victory Capital Management Inc. now owns 75,140 shares of the company's stock valued at $733,000 after acquiring an additional 30,260 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Replimune Group by 106.2% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company's stock valued at $111,000 after acquiring an additional 5,876 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Replimune Group Stock Performance

NASDAQ:REPL opened at $8.94 on Tuesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.94 and a current ratio of 6.94. The stock has a market capitalization of $697.86 million, a P/E ratio of -2.76 and a beta of 0.42. The company has a 50 day moving average price of $5.11 and a 200 day moving average price of $7.28. Replimune Group, Inc. has a fifty-two week low of $2.68 and a fifty-two week high of $17.00.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.95) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). Equities research analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on REPL shares. Leerink Partners upgraded shares of Replimune Group from a "market perform" rating to an "outperform" rating and increased their price objective for the company from $3.00 to $13.00 in a report on Monday. Cantor Fitzgerald raised shares of Replimune Group from a "neutral" rating to an "overweight" rating in a research note on Wednesday, July 30th. Jefferies Financial Group dropped their price target on shares of Replimune Group from $31.00 to $6.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Replimune Group in a research note on Tuesday, October 14th. Finally, Barclays cut shares of Replimune Group from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $17.00 to $3.00 in a research note on Wednesday, July 23rd. Five research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, Replimune Group presently has an average rating of "Hold" and an average target price of $11.00.

Insider Buying and Selling at Replimune Group

In related news, CFO Emily Luisa Hill sold 9,154 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $5.37, for a total transaction of $49,156.98. Following the completion of the transaction, the chief financial officer owned 134,368 shares of the company's stock, valued at approximately $721,556.16. This trade represents a 6.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.20% of the company's stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.